If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
59
results.
Updated on
19/04/2025 [07:37:00]
Results 25 to 50 of 59
Absstract of: US2025093343A1
The invention provides assays and methods for characterization of specific extracellular vesicle (EV) populations, and to the preparation of improved EV compositions for therapy and diagnosis. Specifically, the invention in embodiments thereof provides methods and kits for analyzing blood-derived samples, as well as to the production and use of tissue-derived circulating EV populations characterized by unexpectedly small dimensions and advantageous properties.
Absstract of: WO2025058089A1
The purpose of the present invention is to provide an agent for suppressing amyloid β aggregation/deposition and an agent for suppressing/improving cognitive decline of a subject both of which are expected to have the effect of treating and/or preventing Alzheimer's disease. Specifically, the present invention pertains to an agent for suppressing amyloid β aggregation/deposition or an agent for suppressing/improving cognitive decline of a subject, the agent comprising an extract of a plant belonging to Myrtaceae.
Absstract of: WO2025057945A1
The present application includes: a method for determining whether a patient has cerebral amyloid angiopathy, the method comprising measuring the expression level of α1-acid glycoprotein in a sample collected from the patient; a method for determining the presence or the risk of side effects of a therapy using an anti-amyloid β antibody against Alzheimer's disease, the method comprising measuring the expression level of α1-acid glycoprotein in a sample collected from a patient; and a method for selecting a patient for a therapy using an anti-amyloid β antibody against Alzheimer's disease, the method comprising measuring the expression level of α1-acid glycoprotein in a sample collected from the patient; and the like.
Absstract of: US2023160912A1
Disclosed are an immunoassay method capable of highly sensitively measuring amyloid β in a blood sample, and a kit therefor. The immunoassay method for amyloid β is a method of immunoassay of amyloid β in a blood sample, wherein the immunoassay is carried out in the presence of an anionic polymer such as a dextran sulfate salt or a polystyrene sulfonic acid salt. The kit for immunoassay of amyloid β in a blood sample comprises: an anti-amyloid β antibody or an antigen-binding fragment thereof; and an anionic polymer.
Absstract of: AU2023264886A1
The present disclosure provides devices for the detection and/or quantification of neurotoxic amyloid-type protein aggregates, comprising a doxycycline derivative immobilized on an appropriate surface, as well as electrochemical and immunochemical methods associated to the use of such devices.
Absstract of: KR20250037394A
본 명세서에는 알츠하이머 환자에 특이적인 B 세포 수용체 클론형을 검출하는 제제를 포함하는 알츠하이머 예측 또는 진단용 조성물, 시스템 및 정보제공방법에 관한 것으로, 본 발명의 일 측면에 따른 조성물은 알츠하이머 환자에 특이적인 B 세포 수용체 (B cell receptor, BCR) 클론형을 검출하는 제제를 포함함으로써 방사성 물질을 사용하는 MRI와 PET 스캔의 방법 외에 병리적 특징의 발현이나 축적에 관계없이 비침습적이고 편리한 방식으로 단순히 피험자로부터 분리한 말초혈 단핵구를 이용하여 알츠하이머를 예측 또는 진단할 수 있는 우수한 효과가 있다.
Absstract of: AU2023347307A1
The disclosure relates to lemborexant, a dual orexin receptor antagonist, and compositions and methods for use in treatment of Alzheimer's disease (AD), e.g., in a subject who has AD or who is at risk for developing AD.
Absstract of: US2025084157A1
The invention relates to antibodies, antibody fragments and binding agents that specifically recognize oligomeric tau but do not bind to monomeric tau, fibrillar tau or non-disease associated forms of tau.
Absstract of: WO2025054610A1
Dementia is a brain disease which results in irreversible and progressive loss of cognition and motor activity. Despite global efforts, there are no simple and reliable diagnosis or treatment options. Embodiments of the disclosed technology provide an aptamer-based graphene field-effect transistor (GFET) biosensor platform that has high sensitivity and precision across a range of epidemiologically significant Alzheimer's disease and Parkinson's disease variants, and enables at-home and point-of-care (POC) testing for neurodegenerative diseases. An example method of detecting for detecting a molecular biomarker for dementia of a subject includes receiving a biological sample comprising the molecular biomarker for dementia, contacting the biological sample with a biosensor device comprising a GFET-based detection chip, and detecting a presence of the molecular biomarker for dementia in the biological sample.
Absstract of: WO2025050415A1
Disclosed in the present invention is the use of peripheral blood macrophages in the preparation of a reagent and/or a drug for the diagnosis, prognosis and treatment of Alzheimer's disease (AD). The present invention will open new doors for a better understanding of the disease mechanisms of Alzheimer's disease and may guide development in new directions for early diagnosis, prognosis and treatment, so as to enable early prevention and treatment of Alzheimer's disease.
Absstract of: AU2023264886A1
The present disclosure provides devices for the detection and/or quantification of neurotoxic amyloid-type protein aggregates, comprising a doxycycline derivative immobilized on an appropriate surface, as well as electrochemical and immunochemical methods associated to the use of such devices.
Absstract of: WO2023214324A1
The present invention relates to a method for diagnosing neurodegenerative diseases, wherein said method comprises measuring the JNK3 levels in a biological sample selected from plasma, CSF, and saliva. In an embodiment, said method also comprises measuring P-JNK3.
Absstract of: MX2024009492A
Disclosed herein are methods of diagnosing, selecting, monitoring, and treating subjects with Alzheimer's disease (AD) or suspected of having AD or another disorder associated with amyloid accumulation in the brain.
Absstract of: US2025064417A1
Disclosed are methods for using regional tau PET scans for identifying a subject having or suspected of having, diagnosing, and treating Alzheimer's disease. The methods are particularly useful for treating and diagnosing a patient as susceptible and at risk for developing amyloid-beta and cognitive dysfunction using tau-PET imaging based on regional tau PET measures.
Absstract of: CN118731373A
The invention belongs to the field of biological medicine, and particularly relates to a combination for joint detection of Alzheimer's disease biomarkers and application. The invention provides an application of a biomarker group in detection of Alzheimer's disease, and is characterized in that the biomarker group comprises: a) at least two of APOE4, GDF-15, UCH-L1 and PF4; or b) at least one of APOE4, GDF-15, UCH-L1 and PF4, as well as a phosphorylated Tau protein and a total Tau protein. The invention also provides a kit for detecting the Alzheimer's disease. According to the invention, more effective detection and diagnosis of the Alzheimer's disease are facilitated, and a new path is provided for detection and prevention of AD.
Absstract of: AU2025201059A1
The invention provides anti-Tau antibodies and methods of using the same.
Absstract of: WO2025046049A1
The present invention relates to molecules that are capable of binding to amyloid fibril aggregates. The invention further describes methods for detecting the presence of amyloid fibril aggregates in a sample or a subject. The invention even further describes methods for treating pathologies caused by amyloid fibril aggregates.
Absstract of: US2022397580A1
The present disclosure relates generally to the field of neurology. In particular, the disclosure relates to a method of detecting a neurodegenerative disease in a subject and methods of treatment thereof. The methods include detecting the level of an exosome-bound aggregated biomarker in a sample obtained from the subject, wherein an increased level of the exosome-bound aggregated biomarker as compared to a reference indicates that the subject is suffering from a neurodegenerative disease. Also described are methods for detecting a subject at risk of developing amyloidosis or a neurodegenerative disease, methods for detecting and treating amyloidosis or a neurodegenerative disease in a subject, and methods of determining the aggregation state of a biomarker in a sample.
Absstract of: EP4516923A1
The present application relates to a digested DDIT4L product as a diagnostic marker for Alzheimer's disease, and use thereof in diagnosing Alzheimer's disease. In particular, the present application relates to use of a substance for detecting a digested intron retention (DIR) product encoding DNA-damage-inducible transcript 4 like (DDIT4L) in a sample of a subject in preparing a product for diagnosing Alzheimer's disease or a mild cognitive disorder and/or assessing (e.g., grading or staging) cognitive disorder progression, a related product thereof, and a method for screening a medicament using the DIR product.
Absstract of: AU2023329330A1
Provided herein are antibodies, or fragments thereof, that specifically bind to a microtubule-binding region (MTBR) of tau, and uses thereof. Further provided are methods of detecting species of MTBR in blood or cerebral spinal fluid, and the use of such detection for diagnosing, prognosing, or staging pathological features and/or clinical symptoms of tauopathies, and to choose treatments appropriate for a given disease stage.
Absstract of: US2025067731A1
The present invention provides improved and minimally invasive biomarker-based diagnostics for synucleinopathies (e.g., Parkinson's disease (PD)). The invention further provides assays and methods for analysis of biological samples, for the evaluation and determination of characteristics pertaining to pathological processes associated with α-synuclein, and to methods for determining the suitability of analytical agents for diagnosis of synucleinopathies. More specifically, the invention in embodiments thereof provides improved methods comprising specific detection and quantification of α-synuclein-based biomarkers from low volumes of biological samples.
Absstract of: US2025064417A1
Disclosed are methods for using regional tau PET scans for identifying a subject having or suspected of having, diagnosing, and treating Alzheimer's disease. The methods are particularly useful for treating and diagnosing a patient as susceptible and at risk for developing amyloid-beta and cognitive dysfunction using tau-PET imaging based on regional tau PET measures.
Absstract of: WO2025040574A1
Alzheimer's disease is strongly linked to biological aging and bioenergetic abnormalities. Systemic dysregulation of metabolism is a hallmark of the physiological decline of tissues with age. We aimed to explore untargeted metabolomic profiling of blood samples from amyloid-positive people to distinguish individuals who progressed to cognitive decline from those who remained cognitively intact despite having amyloid deposits in the brain. A minimal signature of 9 metabolites identified decliners and non-decliners of cognitive function in participants with an amyloid load. These findings are of clinical importance as they suggest that a metabolic fingerprint may help to predict patients who will develop cognitive decline. Due to the high prevalence of brain amyloid-positivity in older adults, identifying adults who will have cognitive decline will enable the development of personalized and early interventions. The present invention relates to an in vitro method for predicting cognitive decline in a subject comprising the step of determining the level of at least one metabolite selected in the group consisting of 3-hydroxybutyrate, acetone, triglyceride 48:3, glucose, citrate, succinate, methionine, serine, sphingomyelin d18:1/C26:0 in a biological sample obtained from the subject.
Absstract of: US2022267776A1
Aspects of the disclosure relate to compositions and methods for the diagnosis and/or treatment of certain neurodegenerative diseases, for example those diseases associated with repeat-associated non-ATG (RAN) translation proteins, such as Alzheimer's disease (AD). In some embodiments, the disclosure relates to identifying a subject having a RAN protein-associated disease by detecting expression or activity of repeat-associated non-ATG (RAN) translation proteins (e.g., RAN proteins). In some embodiments, the disclosure relates to methods of treating a RAN protein-associated disease by administering to a subject in need thereof an agent that reduces expression or activity of RAN proteins.
Nº publicación: EP4512413A1 26/02/2025
Applicant:
GUANGDONG JIANTEBO BIOTECHNOLOGY CO LTD [CN]
Guangdong Jiantebo Biotechnology Co., Ltd
Absstract of: EP4512413A1
Use of an interleukin 27 (IL-27) protein in preparation of a product for treating and/or delaying Alzheimer's disease (AD) is provided, belonging to the technical field of biomedicine. The IL-27 protein refers to a recombinant IL-27 protein targeting a therapeutic target II,-27, and is selected from the group consisting of a mouse-derived IL-27 protein and a human-derived IL-27 protein, as well as a mammalian IL-27 protein other than the mouse-derived IL-27 protein and the human-derived IL-27 protein. The recombinant IL-27 protein can effectively alleviate the AD caused by Aβ deposition, and can selectively bind to a target receptor, thereby ensuring an accuracy of test results. The protein receptor is highly expressed in the dentate gyrus region of hippocampus, and guarantees drug targeting to the greatest extent. The recombinant IL-27 protein also shows desirable application prospects, can quickly and effectively improve and alleviate behaviors such as the memory impairment in mice with AD, and has a clinical transformation value.
BOPI
Electronic site
